A
Alfons J.M. van den Eertwegh
Researcher at VU University Amsterdam
Publications - 167
Citations - 21844
Alfons J.M. van den Eertwegh is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Cancer & Melanoma. The author has an hindex of 48, co-authored 140 publications receiving 19426 citations. Previous affiliations of Alfons J.M. van den Eertwegh include VU University Medical Center & Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon,Charles G. Drake,Howard I. Scher,Karim Fizazi,Alberto Bossi,Alfons J.M. van den Eertwegh,Michael Krainer,Nadine Houede,Ricardo Santos,Hakim Mahammedi,Siobhan Ng,Michele Maio,Fabio Franke,Santhanam Sundar,Neeraj Agarwal,Andries M. Bergman,Tudor Ciuleanu,Ernesto Korbenfeld,Lisa Sengeløv,Steinbjørn Hansen,Christopher J. Logothetis,Tomasz M. Beer,M. Brent McHenry,Paul Gagnier,David R. Liu,Winald R. Gerritsen +25 more
TL;DR: There was no significant difference between the ipilimumab group and the placebo group in terms of overall survival in the primary analysis, but there were signs of activity with the drug that warrant further investigation.
Journal Article
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giuseppe Giaccone,Cornelis J. A. Punt,Yoshitaka Ando,Rita Ruijter,Nobusuke Nishi,Marlies E. W. J. Peters,B. Mary E. von Blomberg,Rik J. Scheper,Hans van Vliet,Alfons J.M. van den Eertwegh,Marja Roelvink,Jos H. Beijnen,Heinz Zwierzina,Herbert M. Pinedo +13 more
TL;DR: KRN7000 is well tolerated in cancer patients over a wide range of doses and other therapeutic strategies aiming at reconstitution of the deficient NKT-cell population in cancer Patients may be warranted.
Journal ArticleDOI
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J.M. van den Eertwegh,Jurjen Versluis,H Pieter van den Berg,Saskia J. A. M. Santegoets,R. Jeroen A. van Moorselaar,Tim M. van der Sluis,H.E. Gall,Thomas Harding,Karin Jooss,Israel Lowy,Herbert M. Pinedo,Rik J. Scheper,Anita G.M. Stam,B. Mary E. von Blomberg,Tanja D. de Gruijl,Kristen Hege,Natalie Sacks,Winald R. Gerritsen +17 more
TL;DR: GVAX combined with 3·0 mg/kg ipilimumab is tolerable and safe for patients with mCRPC, and the most common adverse events noted in all 28 patients were injection-site reactions, fatigue, and pyrexia.
Journal ArticleDOI
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage.
Hans van Vliet,B. Mary E. von Blomberg,Nobusuke Nishi,Martine Reijm,Alexandre E. Voskuyl,Ad A. van Bodegraven,Chris H. Polman,Thomas Rustemeyer,Paul Lips,Alfons J.M. van den Eertwegh,Giuseppe Giaccone,Rik J. Scheper,Herbert M. Pinedo +12 more
TL;DR: The present data support the idea that therapies aiming at the in vivo expansion of regulatory NKT cells might help to control immune-mediated damage in autoimmune disease.